Oncolab Co., Ltd.
June 16, 2025
Company Presentation
Oncology
154
OncoLab Co., Ltd. is developing ANGel platform (Antibody-conjugated nanogel) for subcutaneous, sustained delivery of cancer immunotherapeutics.
ANGel enables precise and durable delivery of antibodies, peptides, small molecules, as well as existing ADCs and bispecific antibodies, targeting tumors and immune cells.
In triple-negative breast cancer (TNBC), our lead program achieved ~50% complete remission in preclinical models.
We are now advancing toward clinical translation and global co-development partnerships
Company HQ City:
Goyang-si
Company HQ State:
Gyeonggi-do
Company HQ Country:
Korea, Republic of
Year Founded:
2024
Lead Product in Development:
ANGel – a nanogel-based, non-biodegradable drug delivery platform enabling localized and sustained release of immuno-oncology agents, currently targeting triple-negative breast cancer (TNBC)
CEO
Jongseong Kim
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
Initiation of GLP-compliant toxicology studies in the second half of 2025
Commencement of IND-enabling preparations in 2026
Pre-A funding round to support IND and CMC activities
Initiation of PoC joint studies or technical due diligence with global pharmaceutical companies
What is your next catalyst (value inflection) update?
June or July 2025 – expected initiation of GLP-compliant toxicology studies
Website
www.oncolab.co.kr
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}